Mineralys Therapeutics, Inc. Common Stock (MLYS) — Strategic Asset Allocation Index
Mineralys Therapeutics, Inc. Common Stock (MLYS) has a Strategic Asset Allocation Index of 0.0% as of December 2024. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $191.26 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Mineralys Therapeutics, Inc. Common Stock Strategic Asset Allocation Index (2023–2024)
This chart shows how Mineralys Therapeutics, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 2 annual periods from 2023 to 2024. As of December 2024, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $191.26 Million USD. Explore MLYS cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Mineralys Therapeutics, Inc. Common Stock (2023–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Mineralys Therapeutics, Inc. Common Stock from 2023 to 2024, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see MLYS market cap overview.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 0.0% | $0.00 | $- | $0.00 | $191.26 Million | ▼ -1.0 pp |
| 2023 | 1.0% | $2.48 Million | $- | $2.48 Million | $241.15 Million | — |